Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1753869 | 0.93 | SOS1 (0.42) | SOS1SOS2DRD4OPRM1 | |
| SCHEMBL1753683 | 0.93 | SOS1 (0.40) | SOS1SOS2USP2 | |
| SCHEMBL1753460 | 0.91 | SOS1 (0.39) | SOS1SOS2USP2 | |
| SCHEMBL1753641 | 0.88 | SOS1 (0.42) | SOS1SOS2OPRM1USP2 | |
| SCHEMBL23467579 | 0.87 | DRD4 (0.35) | SOS1SOS2DRD4OPRM1 | |
| SCHEMBL1753643 | 0.87 | DRD4 (0.35) | SOS1SOS2DRD4OPRM1 | |
| SCHEMBL1753717 | 0.85 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL1753876 | 0.85 | SOS1 (0.41) | SOS1SOS2 | |
| SCHEMBL16144786 | 0.83 | SOS1 (0.40) | SOS1SOS2 | |
| SCHEMBL25820321 | 0.83 | DRD4 (0.33) | SOS1SOS2DRD4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024123991-A1 | TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISORDERS WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123999-A1 | TREATMENT OF GRAFT-VERSUS-HOST DISEASE WITH INHIBITORS OF BET FAMILY BDII BROMODOMAIN | POSEIDON INNOVATION 1, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220129-A1 | BENZOYPARAZINE PYRAZINES ANE THEIR USES | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023196720-A2 | LRRK2 INHIBITORS | Brenig Therapeutics, Inc. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | SANOFI (FR) | 2013-10-03 | — | — | US | disclosed |
| EP-1987020-B1 | AZACYCLYL-SUBSTITUTED ARYLDIHYDROISOQUINOLINONES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS | SANOFI SA (FR) | 2012-10-03 | — | — | EP | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| US-8158643-B2 | Substituted diaza-spiro-pyridinone derivatives for use in MCH-1 mediated diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-04-17 | — | — | US | disclosed |
| WO-2011091410-A1 | TRPV4 ANTAGONISTS | GLAXOS SMITHKLINE LLC (US) | 2011-07-28 | — | — | WO | disclosed |
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | JAPAN TOBACCO INC. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | US | disclosed |
| US-20090221641-A1 | Diaza-spiro--nonane derivatives as neurokinin (nk1) antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-09-03 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136778-A1 | NITROGEN-CONTAINING SPIROCYCLIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | REN, PKD1, NR3C2 | SOS1 304/4885SOS2 855/4885DRD4 3287/4885 |
| US-20130261106-A1 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF | DPYD, TYMP, DHFR | SOS1 4472/4885SOS2 3754/4885DRD4 2082/4885 |
| US-20100035909-A1 | NOVEL SUBSTITUTED DIAZA-SPIRO-PYRIDINONE DERIVATIVES FOR USE IN MCH-1 MEDIATED DISEASES | MCHR1, MCHR2, MC1R | SOS1 1295/4885SOS2 3181/4885DRD4 177/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | SOS1 2459/4885SOS2 2500/4885DRD4 4510/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | SOS1 349/4885SOS2 281/4885DRD4 4828/4885 |
| US-20090221641-A1 | Diaza-spiro--nonane derivatives as neurokinin (nk1) antagonists | NPSR1, KISS1R, AVPR1A | SOS1 907/4885SOS2 1994/4885DRD4 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.